Log In
BCIQ
Print this Print this
 

MB07133

  Manage Alerts
Collapse Summary General Information
Company Ligand Pharmaceuticals Inc.
DescriptionLiver prodrug formulation of cytarabine (araC)
Molecular Target DNA polymerase
Mechanism of ActionDNA polymerase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationLiver cancer
Indication DetailsTreat hepatocellular carcinoma (HCC); Treat inoperable hepatocellular carcinoma (HCC)
Regulatory Designation
PartnerHainan Kaihua Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$3.2M

$2.6M

$101.6M


 Deals Details
Get a free BioCentury trial today